Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20968822 | 0.95 | TSHR (0.37) | TSHRALDH1A1GAAL3MBTL1HDAC8 | |
| SCHEMBL18736079 | 0.95 | TSHR (0.34) | TSHRALDH1A1GAAL3MBTL1 | |
| SCHEMBL18349774 | 0.92 | HDAC8 (0.35) | TSHRALDH1A1HDAC8 | |
| SCHEMBL29867869 | 0.89 | TLR2 (0.31) | — | |
| SCHEMBL27228132 | 0.89 | TSHR (0.40) | TSHRALDH1A1HDAC8 | |
| SCHEMBL21497602 | 0.89 | TSHR (0.30) | TSHR | |
| SCHEMBL27228531 | 0.86 | MEN1 (0.42) | GAAHDAC8 | |
| SCHEMBL18349779 | 0.86 | RECQL (0.39) | TSHRALDH1A1HDAC8 | |
| SCHEMBL16905495 | 0.85 | RECQL (0.38) | TSHRALDH1A1GAAHDAC8 | |
| SCHEMBL25244137 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-05-26 | — | — | US | disclosed |
| US-20260062435-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD (SG) | 2026-03-05 | — | — | US | disclosed |
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | WAVE LIFE SCIENCES LTD. (SG) | 2026-02-17 | — | — | US | disclosed |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | WAVE LIFE SCIENCES LTD. (SG) | 2025-09-02 | — | — | US | disclosed |
| US-20250066775-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2025-02-27 | — | — | US | disclosed |
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-05-30 | — | — | US | disclosed |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-11 | — | — | US | disclosed |
| US-20240109931-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-04-04 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-20190008986-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-01-10 | — | — | US | disclosed |
| WO-2018223073-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018223081-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018223056-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-12-06 | — | — | WO | disclosed |
| WO-2018067973-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-04-12 | — | — | WO | disclosed |
| WO-2018067973-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2018-04-12 | — | — | WO | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017192679-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017062862-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-04-13 | — | — | WO | disclosed |
| WO-2017062862-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2017-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062435-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | NSUN3, METTL3, RNASE1 | TSHR 2955/4885ALDH1A1 3830/4885GAA 340/4885 |
| US-12552743-B2 | Oligonucleotide compositions and methods of use thereof | NSUN3, NSUN2, SNRPA1 | TSHR 2252/4885ALDH1A1 3400/4885GAA 824/4885 |
| US-20240175018-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, RNASEL | TSHR 3308/4885ALDH1A1 3065/4885GAA 132/4885 |
| US-20240109931-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF | RNASE1, RNASEH1, NSUN3 | TSHR 3787/4885ALDH1A1 2830/4885GAA 138/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | TSHR 3764/4885ALDH1A1 2846/4885GAA 777/4885 |
| US-20240117347-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | TSHR 3181/4885ALDH1A1 3613/4885GAA 1072/4885 |
| US-12403156-B2 | Oligonucleotides, compositions and methods thereof | TLR9, RNGTT, NT5C3B | TSHR 2966/4885ALDH1A1 4085/4885GAA 2393/4885 |
| US-12637672-B2 | Oligonucleotide compositions and methods thereof | UPF1, SMN1; SMN2, RNGTT | TSHR 1552/4885ALDH1A1 3106/4885GAA 2401/4885 |
| US-20190008986-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | RBM17, HNRNPA2B1, HNRNPA1 | TSHR 3181/4885ALDH1A1 3613/4885GAA 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.